Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Low-dose teclistamab in newly diagnosed multiple myeloma patients

View Full Paper
Ask AI
Bookmark
Share

Authors

JMJosé Emiliano Montelongo-CepedaLTLuz TarinDGDavid Gómez‐Almaguer

Discussion

Loading...

Member takes

Overview

Single-arm trial shows high complete response rates in newly diagnosed multiple myeloma patients, suggesting low-dose teclistamab may improve outcomes.

Key Points

  • This study aims to assess the efficacy of low-dose teclistamab as consolidation in newly diagnosed multiple myeloma.
  • Single-arm phase II study with transplant eligible, treatment-naive patients
  • Participants receive VRd induction therapy followed by low-dose teclistamab consolidation
  • MRD evaluated using flow cytometry one month after teclistamab administration
  • Patients monitored for adverse events graded according to CTCAE v5
  • 11 patients included with median follow-up of 4.3 months
  • 100% overall response rate achieved after teclistamab consolidation
  • All assessed patients achieved MRD-negative complete response
  • Manageable toxicity profile with no grade ≥3 toxicities reported

Cite This Study

Montelongo-Cepeda et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da95https://doi.org/10.1182/blood-2025-4047
View Full Paper
Ask AI
Bookmark
Share